Antengene Biotech

Antengene is a leading commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class and best-in-class therapies for oncology and other life-threatening diseases. Headquartered in China with a global presence, the company leverages its internal R&D capabilities and strategic partnerships to build a robust pipeline of small molecules and biologics. Its flagship product, Xpovio (selinexor), is a first-in-class XPO1 inhibitor approved for multiple hematologic malignancies in several Asia-Pacific markets. Antengene's pipeline includes over 15 programs targeting novel pathways such as mTOR, JAK, and various immune checkpoints. The company aims to address significant unmet medical needs through a dual-engine approach of in-licensing and internal discovery.